Technical Analysis for CTSO - Cytosorbents Corporation

Grade Last Price % Change Price Change
F 8.88 -0.34% -0.03
CTSO closed down 0.34 percent on Thursday, April 22, 2021, on 57 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CTSO trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
200 DMA Resistance Bearish -0.34%
Crossed Above 20 DMA Bullish -0.34%
200 DMA Resistance Bearish 1.49%
Fell Below 20 DMA Bearish 1.49%
Down 3 Days in a Row Weakness 1.49%
Older End-of-Day Signals for CTSO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 6 hours ago
Down 1% about 6 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
200 DMA Resistance about 6 hours ago
Possible NR7 about 6 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cytosorbents Corporation Description

CytoSorbents Corporation, a development stage company, is engaged in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company develops its adsorbent polymer technology for various applications in the medical field, primarily to provide blood purification for acute and chronic health complications associated with blood toxicity. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; for the adjunctive therapy in other critical care applications, including acute respiratory distress syndrome, severe burn injury, trauma, and pancreatitis; to prevent and treat organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and for the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The company is also developing HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Disease Imaging Medical Equipment Injury Dysfunction Kidney Disease Membrane Technology Radiology Interventional Radiology Bypass Toxins Blood Plasma Cytokine Perfusion Organs Transfusion Medicine Renal Dialysis Blood Products Acute Respiratory Distress Syndrome Bypass Surgery Respiratory Distress Sepsis Adjunctive Therapy Cardiopulmonary Bypass Pancreatitis Respiratory Distress Syndrome Toxic Chemicals

Is CTSO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.74
52 Week Low 7.13
Average Volume 262,516
200-Day Moving Average 8.94
50-Day Moving Average 9.30
20-Day Moving Average 8.85
10-Day Moving Average 9.03
Average True Range 0.38
ADX 13.6
+DI 18.25
-DI 19.20
Chandelier Exit (Long, 3 ATRs ) 8.33
Chandelier Exit (Short, 3 ATRs ) 9.18
Upper Bollinger Band 9.39
Lower Bollinger Band 8.31
Percent B (%b) 0.53
BandWidth 12.15
MACD Line -0.03
MACD Signal Line -0.06
MACD Histogram 0.0222
Fundamentals Value
Market Cap 383.4 Million
Num Shares 43.2 Million
EPS -0.53
Price-to-Earnings (P/E) Ratio -16.79
Price-to-Sales 8.19
Price-to-Book 4.45
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.26
Resistance 3 (R3) 9.28 9.17 9.20
Resistance 2 (R2) 9.17 9.08 9.16 9.18
Resistance 1 (R1) 9.03 9.02 8.97 9.01 9.16
Pivot Point 8.92 8.92 8.89 8.91 8.92
Support 1 (S1) 8.77 8.82 8.72 8.75 8.60
Support 2 (S2) 8.66 8.76 8.65 8.58
Support 3 (S3) 8.52 8.66 8.56
Support 4 (S4) 8.50